Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 2, 2013, Pages 206-211

  Metcalfe, John Z ^a   Cattamanchi, Adithya ^a   McCulloch, Charles E ^b   Lew, Justin D ^c   Ha, Ngan P ^c   Graviss, Edward A ^c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Imprecision; Interferon release assay; QuantiFERON; Repeatability

Indexed keywords

ADULT; ARTICLE; CLINICAL PRACTICE; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT REPEATABILITY; PRIORITY JOURNAL; QUALITY CONTROL; TUBERCULOSIS;

ADULT; FEMALE; HUMANS; IMMUNOASSAY; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS;

EID: 84872583104     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201203-0430OC     Document Type: Article

References (52)

1. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Morb Mortal Wkly Rep Recomm Rep 2010;59:1-25.
2. Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 2007;4:e208.
3. Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, Smith PG, Sriram N, Wongsrichanalai C, Linke R, et al. Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol 2006;4:S20-S32.
4. Derion T. Considerations for the planning and conduct of reproducibility studies of in vitro diagnostic tests for infectious agents. Biotechnol Annu Rev 2003;9:249-258.
5. Cellestis. Validation report QuantiFERON-TB Gold In-Tube: reproducibility study. 2006 [accessed 2011 Dec 16]. Available from: http:// www.cellestis.com/IRM/Company/ShowPage.aspx/PDFs/1359-10000000/ ValidationReportQFTInTubeReproducibilityStudy
6. Detjen AK, Loebenberg L, Grewal HM, Stanley K, Gutschmidt A, Kruger C, Du Plessis N, Kidd M, Beyers N, Walzl G, et al. Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol 2009;16:1170-1175.
7. PaiM, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, Reingold AL, Colford JM Jr, Riley LW, Menzies D. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006;174:349-355.
8. Veerapathran A, Joshi R, Goswami K, Dogra S, Moodie EE, Reddy MV, Kalantri S, Schwartzman K, Behr MA, Menzies D, et al. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PloS One 2008;3:e1850.
9. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009;180:49-58.
10. Herrmann JL, Belloy M, Porcher R, Simonney N, Aboutaam R, Lebourgeois M, Gaudelus J, De Losangeles L, Chadelat K, Scheinmann P, et al. Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS ONE 2009;4:e4130.
11. Chee CB, Lim LK, Barkham TM, Koh DR, Lam SO, Shen L, Wang YT. Use of a T cell interferon-gamma release assay to evaluate tuberculosis risk in newly qualified physicians in Singapore healthcare institutions. Infect Control Hosp Epidemiol 2009;30:870-875.
12. Lee K, Han MK, Choi HR, Choi CM, Oh YM, Lee SD, Kim WS, Kim DS, Woo JH, Shim TS. Annual incidence of latent tuberculosis infection among newly employed nurses at a tertiary care university hospital. Infect Control Hosp Epidemiol 2009;30:1218-1222.
13. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON-TB Gold In-Tube assay. Clin Vaccine Immunol 2008;15:425-432.
14. Pollock NR, Campos-Neto A, Kashino S, Napolitano D, Behar SM, Shin D, Sloutsky A, Joshi S, Guillet J, Wong M, et al. Discordant QuantiFERON-TB Gold Test results among US healthcare workers with increased risk of latent tuberculosis infection: a problem or solution? Infect Control Hosp Epidemiol 2008;29:878-886.
15. Yoshiyama T, Harada N, Higuchi K, Nakajima Y, Ogata H. Estimation of incidence of tuberculosis infection in health-care workers using repeated interferon-gamma assays. Epidemiol Infect 2009;137:1691- 1698.
16. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE 2009;4: e8517.
17. Tuuminen T, Tavast E, Vaisanen R, Himberg JJ, Seppala I. Assessment of imprecision in gamma interferon release assays for the detection of exposure to Mycobacterium tuberculosis. Clin Vaccine Immunol 2010; 17:596-601.
18. Ringshausen FC, Nienhaus A, Torres Costa J, Knoop H, Schlosser S, Schultze-Werninghaus G, Rohde G. Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers. Clin Vaccine Immunol 2011;18:1176-1182.
19. Janetzki S, Schaed S, Blachere NE, Ben-Porat L, Houghton AN, Panageas KS. Evaluation of Elispot assays: influence of method and operator on variability of results. J Immunol Methods 2004;291:175-183.
20. Ringshausen FC, Nienhaus A, Schablon A, Schlosser S, Schultze- Werninghaus G, Rohde G. Predictors of persistently positive Mycobacterium- tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis 2010;10:220.
21. Metcalfe JZ, Parker M, Lew J, Graviss EA. Within-subject variability of the QuantiFERON-TB Gold In-Tube assay in a large cohort of low risk subjects. Presented at the 3rd Global Symposium on IGRAs 2012, January 15, 2012, Waikoloa, Hawaii.
22. Clinical and Laboratory Standards Institute. Ep21-a, estimation of total analytical error for clinical laboratory methods; approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2003.
23. Porsa E, Cheng L, Seale MM, Delclos GL, Ma X, Reich R, Musser JM, Graviss EA. Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin Vaccine Immunol 2006; 13:53-58.
24. Porsa E, Cheng L, Graviss EA. Comparison of an ESAT-6/CFP-10 peptide-based enzyme-linked Immunospot assay to a tuberculin skin test for screening of a population at moderate risk of contracting tuberculosis. Clin Vaccine Immunol 2007;14:714-719.
25. Grimes CZ, Hwang LY, Williams ML, Austin CM, Graviss EA. Tuberculosis infection in drug users: interferon-gamma release assay performance. Int J Tuberc Lung Dis 2007;11:1183-1189.
26. Cruz AT, Geltemeyer AM, Starke JR, Flores JA, Graviss EA, Smith KC. Comparing the tuberculin skin test and T-spot TB blood test in children. Pediatrics 2011;127:e31-e38.
27. Cellestis Limited. (2010). QuantiFERON-TB Gold In-Tube: package insert. Carnegie, Victoria, Australia [accessed 2012 May 4]. Available from: Http://www.Cellestis.Com/irm/content/pdf/quantiferon%20us %20verg- jan2010%20no%20trims.Pdf
28. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981.
29. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
30. Powell RD III, Whitworth WC, Bernardo J, Moonan PK, Mazurek GH. Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests. PLoS ONE 2011;6:e20061.
31. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
32. Diggle PJ. An approach to the analysis of repeated measurements. Biometrics 1988;44:959-971.
33. Furcolow ML, Watson KA, Charron T, Lowe J. A comparison of the tine and mono-vacc tests with the intradermal tuberculin test. Am Rev Respir Dis 1967;96:1009-1027.
34. Erdtmann FJ, Dixon KE, Llewellyn CH. Skin testing for tuberculosis: antigen and observer variability. JAMA 1974;228:479-481.
35. Bearman JE, Kleinman H, Glyer VV, Lacroix OM. A study of variability in tuberculin test reading. Am Rev Respir Dis 1964;90:913-919.
36. Chaparas SD, Vandiviere HM, Melvin I, Koch G, Becker C. Tuberculin test: variability with the Mantoux procedure. Am Rev Respir Dis 1985; 132:175-177.
37. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep Recomm Rep 2000;49:1-51.
38. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2012;67:62-70.
39. Zwerling A, Cloutier-Ladurantaye J, Pietrangelo F. Conversions and reversions in health care workers inMontreal, Canada using QuantiFERONTB- Gold In-Tube [abstract]. Am J Respir Crit Care Med 2009;179: A1012.
40. Belknap RWK, Teeter L. Interferon-gamma release assays (IGRAS) in serial testing for latent tuberculosis infection in U.S. health care workers [abstract]. Am J Respir Crit Care Med 2010;181:A2263.
41. Mancuso JD, Mazurek GH, Tribble D, Olsen C, Aronson NE, Geiter L, Goodwin D, Keep LW. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med 2012;185:427-434.
42. Fong KS, Tomford JW, Teixeira L, Fraser TG, Vanduin D, Yen- Lieberman B, Gordon SM, Miranda C. Challenges of interferongamma release assay conversions in serial testing of health care workers in a tuberculosis control program. Chest 2012;142:55-62.
43. Gray J, Reves R, Johnson S, Belknap R. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIVinfected patients at low risk for tuberculosis. Clin Infect Dis 2012;54: e20-23.
44. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21.
45. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, Reddy MV, Kalantri A, Hill PC, Menzies D, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009;13:84-92.
46. Quan H, Shih WJ. Assessing reproducibility by the within-subject coefficient of variation with random effects models. Biometrics 1996;52: 1195-1203.
47. Krouwer JS, Rabinowitz R. How to improve estimates of imprecision. Clin Chem 1984;30:290-292.
48. van Zyl-Smit RN, Binder A, Meldau R, Mishra H, Semple PL, Theron G, Peter J, Whitelaw A, Sharma SK, Warren R, et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS ONE 2011;6:e28815.
49. Metcalfe JZ, Cattamanchi A, Vittinghoff E, Ho C, Grinsdale J, Hopewell PC, Kawamura LM, Nahid P. Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects. Am J Respir Crit Care Med 2010;181:87-93.
50. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon- {gamma} release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011;183:88-95.
51. American Society for Testing and Materials (ASTM) International. What are repeatability and reproducibility? March/April 2009 [accessed 2012 July 25]. Available from: http://www.Astm.Org/SNEWS/MA- 2009/datapoints-ma09.html
52. American Society for Testing and Materials. E456 standard terminology relating to quality and statistics, 2012 [accessed 2012 July 25]. Available from: http://www.Astm.Org/Standards/E456.htm